Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737213 | 1.00 | CYP11B1 (0.53) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL7479989 | 0.88 | CYP11B1 (0.47) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL11009980 | 0.87 | CYP11B1 (0.47) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL23832223 | 0.87 | CYP11B1 (0.47) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL11013190 | 0.87 | CYP11B1 (0.47) | CYP11B1CYP11B2CA1CA2GSK3B | |
| Dimethylformamide SCHEMBL7479987 | 0.85 | CYP11B1 (0.46) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL23839943 | 0.83 | CYP11B1 (0.48) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL9476052 | 0.81 | CYP11B1 (0.51) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL5098916 | 0.80 | CYP11B1 (0.43) | CYP11B1CYP11B2CA1CA2FNTA | |
| SCHEMBL5098910 | 0.80 | CYP11B1 (0.43) | CYP11B1CYP11B2CA1CA2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| CN-1370167-A | Novel bridged bispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | CN | disclosed |
| EP-1192157-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077000-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | CYP11B1 281/4885CYP11B2 253/4885CA1 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.